End-Unitiolas
End-Unitiolas Uses, Dosage, Side Effects, Food Interaction and all others data.
End-Unitiolas is a traditional chelating agent developed by British biochemists at Oxford University during World War II. It was developed as an experimental antidote against the arsenic-based poison gas Lewisite. It has been used clinically since 1949 in arsenic, cadmium and mercury poisoning. In addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper. End-Unitiolas has toxic potential, and its use may be followed by a variety of adverse effects.
Due to its oily nature, dimercaprol is not absorbed orally and its administration requires a deep intra-muscular injection that is extremely painful and allergenic. It was found to mobilize and relocate lead to the brain, increasing its neurotoxic effects. Despite that fact that dimercaprol increases cadmium excretion, there is an associated increase in kidney cadmium concentration. Because of this, dimercaprol must be avoided in patients with cadmium toxicity.
Trade Name | End-Unitiolas |
Availability | Prescription only |
Generic | Dimercaprol |
Dimercaprol Other Names | 1,2-dithioglycerol, 2,3-dimercaptopropanol, 2,3-dithiopropanol, 2,3-Mercaptopropanol, British anti-lewisite, British antilewisite, Dimercaprol, Dimercaprolum, Dimercaptopropanol, Dithioglycerine, Dithioglycerol, Sulfactin |
Related Drugs | BAL In Oil |
Type | |
Formula | C3H8OS2 |
Weight | Average: 124.225 Monoisotopic: 124.001656258 |
Groups | Approved |
Therapeutic Class | |
Manufacturer | |
Available Country | Lithuania |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
End-Unitiolas is a chelating agent used as an antidote to arsenic, gold, and mercury poisoning, as well as acute lead poisoning in combination with edetate calcium disodium.
For the treatment of arsenic, gold and mercury poisoning. Indicated in acute lead poisoning when used concomitantly with edetate calcium disodium (DB00974).
End-Unitiolas is also used to associated treatment for these conditions: Arsenic Poisoning, Poisoning, Lead, Acute Mercury poisoning, Gold poisoning
How End-Unitiolas works
The sulfhydryl groups of dimercaprol form complexes with certain heavy metals thus preventing or reversing the metallic binding of sulfhydryl-containing enzymes. The complex is excreted in the urine.
Toxicity
The intramuscular LD50 in rats is approximately 105 mg/kg; intraperitoneally 140 mg/kg. The intraperitoneal LD80 in mice is approximately 125 mg/kg. End-Unitiolas has been shown in animal experiments to increase brain deposition of arsenite, organic mercury compounds and increase the toxicity of cadmium and lead. End-Unitiolas has been shown to induce seizure in animal studies and also is nephrotoxic.
Food Interaction
No interactions found.End-Unitiolas Hypertension interaction
[Moderate] Dose-related increase in systolic and diastolic blood pressure, with or without accompanying tachycardia, is the most frequently reported adverse effect of dimercaprol therapy.
Blood pressure may rise 15 to 30 minutes following injection and usually returns to normal within 2 hours.
Therapy with dimercaprol should be administered cautiously in patients with hypertension.
Clinical monitoring of blood pressure is recommended.
End-Unitiolas multivitamins interaction
[Major] ADJUST DOSING INTERVAL: End-Unitiolas can form a nephrotoxic chelate with certain metals such as cadmium, iron, and selenium.
Preparations containing iron or selenium salts should not be administered during chelation therapy with dimercaprol and for at least 24 hours after the last dose of dimercaprol.
End-Unitiolas Drug Interaction
Unknown: aspirin, aspirin, dexamethasone, dexamethasone, dextran, low molecular weight, dextran, low molecular weight, acetaminophen, acetaminophen, multivitamin, multivitamin, riboflavin, riboflavin, pyridoxine, pyridoxine, ascorbic acid, ascorbic acid, ergocalciferol, ergocalciferol, phytonadione, phytonadione
End-Unitiolas Disease Interaction
Major: hepatic dysfunction, renal dysfunctionModerate: peanut allergy, hemolysis/G6PD deficiency, hypertension
Elimination Route
After intra-muscular injection.
Half Life
The drug has a short half life.
Elimination Route
Urine.
Innovators Monograph
You find simplified version here End-Unitiolas